ES2161246T3 - Factor transformante de crecimiento alfa h1. - Google Patents

Factor transformante de crecimiento alfa h1.

Info

Publication number
ES2161246T3
ES2161246T3 ES94916791T ES94916791T ES2161246T3 ES 2161246 T3 ES2161246 T3 ES 2161246T3 ES 94916791 T ES94916791 T ES 94916791T ES 94916791 T ES94916791 T ES 94916791T ES 2161246 T3 ES2161246 T3 ES 2161246T3
Authority
ES
Spain
Prior art keywords
tgf
polypeptide
alfa
growth
sub
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94916791T
Other languages
English (en)
Inventor
Paul S Meissner
Rebecca Fuldner
Mark D Adams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Application granted granted Critical
Publication of ES2161246T3 publication Critical patent/ES2161246T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCRIBE UN POLIPEPTIDO HUMANO TGF AL -H1, Y UN DNA (RNA), QUE CODIFICA PARA DICHOS POLIPEPTIDOS TGF{SUB,{AL}}-H1. TAMBIEN SE PROPORCIONA UN PROCEDIMIENTO DE PRODUCCION DE DICHO POLIPEPTIDO MEDIANTE TECNICAS RECOMBINANTES, Y PARA PRODUCIR ANTICUERPOS Y ANTAGONISTAS CONTRA DICHO POLIPEPTIDO. DICHOS POLIPEPTIDOS SE PUEDEN COMBINAR CON UN TRANSPORTADOR FARMACEUTICO ADECUADO O DILUYENTE, PARA PROPORCIONAR EFECTOS DIAGNOSTICOS, TERAPEUTICOS, Y/O PROFILACTICOS CONTRA VARIAS ENFERMEDADES. ASIMISMO, SE PROPORCIONAN METODOS DE UTILIZACION DE DICHOS ANTICUERPOS Y ANTAGONISTAS, PARA INHIBIR EL TGF{SUB,{AL}}-H1, CON FINALIDADES TERAPEUTICAS.
ES94916791T 1994-03-08 1994-05-12 Factor transformante de crecimiento alfa h1. Expired - Lifetime ES2161246T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/208,008 US5633147A (en) 1994-03-08 1994-03-08 Transforming growth factor αH1

Publications (1)

Publication Number Publication Date
ES2161246T3 true ES2161246T3 (es) 2001-12-01

Family

ID=22772852

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94916791T Expired - Lifetime ES2161246T3 (es) 1994-03-08 1994-05-12 Factor transformante de crecimiento alfa h1.

Country Status (14)

Country Link
US (1) US5633147A (es)
EP (2) EP0759067B1 (es)
JP (1) JPH09509846A (es)
KR (1) KR970701776A (es)
CN (1) CN1087344C (es)
AT (1) ATE205254T1 (es)
AU (1) AU681406B2 (es)
CA (1) CA2184583A1 (es)
DE (1) DE69428214T2 (es)
DK (1) DK0759067T3 (es)
ES (1) ES2161246T3 (es)
PT (1) PT759067E (es)
WO (1) WO1995024466A1 (es)
ZA (1) ZA943465B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020188110A1 (en) * 1994-03-08 2002-12-12 Human Genome Sciences, Inc. Transforming growth factor alpha HI
US7186688B1 (en) * 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
ES2249762T3 (es) 1994-03-08 2006-04-01 Human Genome Sciences, Inc. Factor de crecimiento del endotelio vascular 2.
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US7109308B1 (en) * 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7153827B1 (en) * 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6074839A (en) * 1994-03-08 2000-06-13 Human Genome Sciences, Inc. Transforming growth factor αHI
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6410506B1 (en) 1995-05-19 2002-06-25 Human Genome Sciences, Inc. Transforming growth factor α HII
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
EP1131350A4 (en) * 1998-11-19 2005-05-04 Millennium Pharm Inc NUCLEIC ACIDS AND POLYPEPTIDES AND CORRESPONDING USES THEREOF
US7294482B2 (en) * 1998-11-19 2007-11-13 Millennium Pharmaceuticals, Inc. EGF-like nucleic acids
US7223724B1 (en) * 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
ATE364315T1 (de) * 1999-04-26 2007-07-15 Applied Protein Sciences Llc Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
US20020099008A1 (en) 1999-04-26 2002-07-25 Daniel R. Twardzik Method for stimulating hematopoiesis using tgf-alpha
EP1210102B1 (en) * 1999-08-19 2010-04-07 Applied Protein Sciences, LLC Tgf-alpha polypeptides, functional fragments and methods of use therefor
US20020193301A1 (en) 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
MXPA02003434A (es) * 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
GB0020953D0 (en) * 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
WO2002083850A2 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
CA2444632A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
AU2002252631A1 (en) * 2001-04-13 2002-10-28 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20050014730A1 (en) * 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
MX2010003718A (es) * 2007-10-19 2010-04-21 Genentech Inc Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI890312A7 (fi) * 1988-01-25 1989-07-26 Oncogen Amfireguliini: uusi bifunktionaalinen kasvua moduloiva glykoproteiini
US5115096A (en) * 1988-04-15 1992-05-19 Oncogen Amphiregulin: a bifunctional growth modulating glycoprotein
US5256643A (en) * 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein

Also Published As

Publication number Publication date
AU6835094A (en) 1995-09-25
EP1063293A3 (en) 2001-07-11
DE69428214D1 (de) 2001-10-11
JPH09509846A (ja) 1997-10-07
DK0759067T3 (da) 2001-10-22
EP0759067A4 (en) 1997-10-22
EP0759067B1 (en) 2001-09-05
EP0759067A1 (en) 1997-02-26
AU681406B2 (en) 1997-08-28
EP1063293A2 (en) 2000-12-27
ZA943465B (en) 1995-11-20
US5633147A (en) 1997-05-27
KR970701776A (ko) 1997-04-12
PT759067E (pt) 2002-02-28
CN1087344C (zh) 2002-07-10
ATE205254T1 (de) 2001-09-15
DE69428214T2 (de) 2002-06-27
CA2184583A1 (en) 1995-09-14
CN1143386A (zh) 1997-02-19
WO1995024466A1 (en) 1995-09-14

Similar Documents

Publication Publication Date Title
ES2161246T3 (es) Factor transformante de crecimiento alfa h1.
DK0751992T3 (da) Karendotelvækstfaktor 2
ES2068791T1 (es) Metodos y acido desoxirribonucleico para la preparacion de proteina de factor de tejido.
AU1724795A (en) Human tissue inhibitor of metalloproteinase-4
ES8401777A1 (es) Procedimiento para producir un polipeptido.
HUP9801122A2 (hu) Osteoprotegerin
EP0994724A4 (en) METHODS AND COMPOSITIONS TO PREVENT THE REPRODUCTION OF HIV-1
DE69433371D1 (de) Polypeptid, fähig zur Inhibierung der Bindung zwischen menschliches IL-6 und dessen Rezeptor
HUP0003533A2 (hu) Interleukin-18-at kötő fehérjék, előállításuk és alkalmazásuk
HUP0100436A2 (hu) Emlős citokinszerű polipeptid-10
AU8502198A (en) Method for treating vascular proliferative diseases with p27 and fusions thereof
WO2000015790A3 (en) Leptin induced genes
FI911780A0 (fi) Terapeutiska peptider.
ATE306549T1 (de) C-c ckr-1, ein c-c chemokin rezeptor
WO2002096467A3 (en) Pharmaceutical use for secreted bacterial effector proteins
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
DE69333412D1 (de) Übergangszustand-analoga des kokains, ihre verwendung zur herstellung von kataltischen antikörpern gegen kokain und verwendung derselben in diagnose und therapie
ATE174629T1 (de) Herstellung von proteinen mittels protein 7b2
DK0588118T3 (da) Carboxypeptidaselignende protein knyttet til knogler samt fremgangsmåde til fremstilling deraf
NO975565L (no) Benstimulerende faktor
NO890174L (no) Rekombinante interleukin-1alfa-polypeptider.
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
HUP9702147A2 (hu) Humán DNáz I variánsok
PT88913A (pt) Processo para a preparacao da proteina pp4-x anticoagulante
Wakitani et al. Vasodilator properties of a family of bioactive atrial peptides in isolated perfused rat kidneys

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 759067

Country of ref document: ES